Stirling Anglian Pharmaceuticals

A UK based pharmaceutical company, part of the Kelso Pharma Group

Value based solutions to healthcare

Our purpose is to bring innovative, value added, specialty branded medicines to the UK that can provide benefits to our patients and populations whilst reducing the cost burden to the NHS and helping our healthcare system to curb waste. At a time when there is such pressure on the NHS to reduce costs we believe we offer a real and practical solution.

We work closely with stakeholders across the NHS to identify real-world problems, and develop value-based solutions that support the delivery of efficient and cost-effective healthcare.

SAP

About Stirling Anglian Pharmaceuticals

Value-based solutions

Founded in 2013, Stirling Anglian Pharmaceuticals is a UK based pharmaceutical company, and part of the Kelso Pharma Group.
Stirling Anglian is completely committed to improving patient care and medicines optimisation.

We have sourced and developed a portfolio of high quality, patient-centric medicines designed to benefit health outcomes and help the NHS curb waste. We work closely with stakeholders across the NHS to identify real-world problems and develop value-based solutions that support the delivery of efficient and cost-effective healthcare. By addressing patient compliance issues, we offer real and practical solutions to waste management and supply these at the lowest possible cost.

SAP

Company History

Milestones

  • 2013Company Incorporation

    Founded by the late Andrew Perrie, the business remained under family management until 2021, when it was acquired by the Kelso Pharma Group.

  • 2014CosmoCol® (macrogol 3350) & theiCal-D3® (calcium / vitamin D3 1000mg/880iu)

    UK Marketing Authorisations granted, products launched in the marketplace

  • 2015Stirlescent® 250 mg Effervescent Tablets (250mg naproxen)

    UK Marketing Authorisation granted, product launched in the marketplace

  • 2019Acepiro® (acetylcysteine 600 mg effervescent tablets)

    UK Marketing Authorisation granted, product launched in 2021 (20 tablet pack) and 2023 (30 tablet pack)

  • 2021Initiation of Export Business

    We expand into the CIS market and begin the regulatory approval process in the Middle East & North Africa (MENA) region

  • 2022Stirling Anglian Pharmaceuticals becomes a part of Kelso Pharma

    Apposite Capital-backed Kelso Pharma acquires Stirling Anglian Pharmaceuticals

  • 2023Gaining Two New Dermatology Products

    Acquisition of two marketing authorisations for prescription medicines for the treatment of actinic keratoses and plaque psoriasis

Our Therapy Areas

Innovative products focused on the needs of patients

Respiratory

Effervescent Tablets

  • Once a day dose compared to large number of capsules
  • The tablet dissolves in half a glass of water to form a citrus flavoured solution to drink
  • Improve compliance

Gastrointestinal

Instant drinks

Instant Drinks

  • Taste pleasant and come in a range of flavours and strengths
  • Supplied as a single doe so no measuring required
  • Improve compliance

Nutrition & Blood

Chewable Tablets

  • Directed at patients with swallowing difficulties
  • Packaged in easy-to-open foil strips and can be taken “on the go”
  • Improve compliance

Musculoskeletal

Effervescent Tablets

  • Reduce the risk of drug-induced oesophagitis
  • Easy and convenient to take with single tablet dissolving in a whole glass of water to form a blackcurrant flavoured solution to drink
  • Improve compliance

Pharmaceutical Products

Our Products

Reporting of side effects: If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Within the UK you can report side effects directly via the Yellow Card Scheme at www.yellowcard.mhra.gov.uk

Home
This website uses cookies to improve your experience.
Privacy Policy